Shares of Lantheus Holdings Inc (NASDAQ:LNTH) gapped down before the market opened on Wednesday after an insider sold shares in the company. The stock had previously closed at $13.65, but opened at $15.35. Lantheus shares last traded at $15.35, with a volume of 2355700 shares.
Specifically, SVP Timothy G. Healey sold 3,696 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $19.58, for a total transaction of $72,367.68. Following the sale, the senior vice president now directly owns 64,582 shares in the company, valued at $1,264,515.56. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO John W. Crowley sold 3,866 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $23.52, for a total value of $90,928.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,217 shares of company stock worth $648,368. Company insiders own 2.30% of the company’s stock.
Several research analysts have recently commented on LNTH shares. Zacks Investment Research raised Lantheus from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a report on Saturday, January 27th. BidaskClub lowered Lantheus from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. ValuEngine raised Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, February 3rd. Finally, Credit Suisse Group boosted their price objective on Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $24.75.
Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Monday, February 26th. The medical equipment provider reported $0.12 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.20 by ($0.08). Lantheus had a negative return on equity of 46.62% and a net margin of 37.23%. The business had revenue of $81.24 million for the quarter, compared to analysts’ expectations of $78.57 million. During the same period in the previous year, the firm posted $0.18 EPS. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. sell-side analysts predict that Lantheus Holdings Inc will post 1.29 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of LNTH. Sei Investments Co. boosted its stake in Lantheus by 189.6% in the third quarter. Sei Investments Co. now owns 7,829 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 5,126 shares in the last quarter. Bank of Montreal Can boosted its stake in Lantheus by 371.6% in the fourth quarter. Bank of Montreal Can now owns 6,819 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 5,373 shares in the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in Lantheus in the second quarter worth approximately $141,000. Financial Gravity Companies Inc. purchased a new stake in Lantheus in the fourth quarter worth approximately $158,000. Finally, Cambria Investment Management L.P. purchased a new stake in Lantheus in the third quarter worth approximately $198,000. 91.60% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3228245/lantheus-lnth-shares-gap-down-after-insider-selling.html.
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.